Infertility-Related Depression and Anxiety in Male Partners: What Fertility Clinics Miss

Most fertility clinic mental health screening focuses on the patient carrying the pregnancy. That framing misses half the couple. Male partners experience clinically significant depression and anxiety during infertility treatment at rates that rival those seen in the patient, and their distress predicts treatment dropout, relationship strain, and downstream PMAD risk in the dyad. Most fertility clinics screen neither partner systematically; the male partner goes unscreened almost universally.

Why Male Partner Distress Goes Undetected

The fertility clinic visit is structured around the patient's body. Monitoring appointments, retrieval procedures, and medication protocols center on the patient's physiology. The male partner attends consultations and perhaps one procedural appointment. The clinical gaze rarely lands on him. When distress does surface, it tends to be reframed as support fatigue or stoic coping rather than recognized as a condition warranting clinical attention.

Male partners are also less likely to self-disclose. Research consistently shows that men underreport psychological symptoms on self-report instruments, particularly in medical settings where the primary reason for the visit is unrelated to mental health. Without a structured, normalized screening protocol that names mental health as part of fertility treatment for both partners, male distress will not surface in the clinical record.

Prevalence and Risk Stratification

Clinically significant depressive symptoms appear in 10 to 15 percent of male partners during active IVF treatment. Anxiety rates reach 20 percent or higher during the two-week wait. Rates are elevated in specific subgroups that fertility clinicians encounter routinely:

Male-factor infertility: Partners with a male-factor diagnosis carry higher rates of depression and shame-related distress. The diagnosis often arrives as a shock and sits uncomfortably with social norms around male competence and reproductive identity.

Prior pregnancy loss: Partners who have been through a prior pregnancy loss, particularly a late loss, carry trauma responses that may not be formally identified. When a new cycle begins, conditioned anticipatory anxiety activates.

Repeated cycle failure: Each failed cycle compounds cumulative distress. Partners who have been through multiple retrievals or transfers without success show higher PHQ-9 scores than those in earlier treatment phases.

Socially isolated couples: Partners who have not disclosed infertility to family or social networks are managing the experience without external support. Isolation amplifies distress and reduces access to informal coping.

When to Screen

Three time points in fertility treatment capture the highest-stakes clinical moments for male partner screening:

Before the first retrieval or transfer. Baseline PHQ-9 and GAD-7 establish whether pre-existing depression or anxiety is present. Partners with scores above threshold before treatment starts should be offered a referral before treatment proceeds; undertreated depression during treatment predicts worse outcomes for both partners.

At the positive beta-hCG. Many partners experience a spike in anxiety at pregnancy confirmation rather than relief. The shift from treatment anxiety (will it work?) to pregnancy anxiety (will it continue?) is a clinical transition that often goes unacknowledged.

After a failed cycle or pregnancy loss. Partners who experience failed cycles or early pregnancy loss are at highest acute risk. A brief PHQ-9 at the follow-up appointment after a negative or loss outcome catches the most acute presentations.

Practical Screening Integration

Adding male partner screening does not require a new appointment. Digital intake forms sent to both partners' separate email addresses before the consultation generate scores before the clinician enters the room. If paper administration is used, separate clipboard distribution in different seating reduces social desirability bias.

A PHQ-9 score of 10 or above, or a GAD-7 score of 8 or above, warrants a direct conversation and a referral offer. Scores below threshold should be documented in the record and rescreened at the next major treatment inflection point.

What to Say When a Partner Screens Positive

The clinical language for raising a positive result matters. Framing mental health as part of the treatment plan, not an adjacent concern, reduces resistance:

"Your score suggests you are carrying more distress right now than most people can manage without support. That is not unusual at this stage, and it affects the experience for both of you. I'd like to connect you with someone who works specifically with people going through this."

Avoid language that positions the referral as optional or secondary to the patient's physical treatment. A referral offered with the same clinical weight as a medication recommendation is more likely to be acted on.